Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04675827
Title De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Pertuzumab/trastuzumab/hyaluronidase-zzxf

Age Groups: adult | senior
Covered Countries FRA | BEL


No variant requirements are available.